Waypoint Capital Advisors, LLC Prometheus Biosciences, Inc. Transaction History

Waypoint Capital Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 13, 2023	SELL	$103.46 - $126.29 $1.73 Million - $2.11 Million	-16,715 Reduced 9.76%	154,466 $16.6 Million
Q4 2022 Jan 23, 2023	SELL	$36.06 - $117.21 $789,497 - $2.57 Million	-21,894 Reduced 11.34%	171,181 $0
Q3 2022 Oct 17, 2022	BUY	$28.17 - $59.01 $1.14 Million - $2.38 Million	40,410 Added 26.47%	193,075 $11.4 Million
Q2 2022 Jul 18, 2022	SELL	$22.39 - $38.94 $1.86 Million - $3.24 Million	-83,091 Reduced 35.24%	152,665 $4.31 Million
Q1 2022 Apr 19, 2022	BUY	$30.13 - $50.0 $2.5 Million - $4.15 Million	83,091 Added 54.43%	235,756 $8.73 Million
Q4 2021 Feb 07, 2022	BUY	$22.28 - $39.54 $3.4 Million - $6.04 Million	152,665 New	152,665 $6.04 Million

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Waypoint Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Waypoint Capital Advisors, LLC with notifications on news.